Series A Funding will be used to advance Mosanna's nasal spray therapy through Phase 2 Clinical TrialsBiotech veteran David Weber has been appointed CEO...
Series A funding to advance MOS118 through Phase 2 clinical trials
Biotech veteran David Weber appointed CEO to drive clinical development
Obstructive sleep apnea affects nearly...